|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021079,
umls-concept:C0021080,
umls-concept:C0023911,
umls-concept:C0033085,
umls-concept:C0037993,
umls-concept:C0078140,
umls-concept:C0173022,
umls-concept:C0393022,
umls-concept:C0442711,
umls-concept:C1134564,
umls-concept:C1412099,
umls-concept:C1524063
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-5-27
|
|
pubmed:abstractText |
An ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) is a challenge. Until 2000 systemic multidrug immunosuppression and splenectomy was the gold standard with poor results. Application of local administration with prostagrandin E1 (PGE1) and steroids via a portal vein (PV) catheter dramatically improved the survival from 20% to 60% but PV thrombus became a problem (35%). To solve it, an hepatic arterial (HA) catheter was used instead of a PV catheter and splenectomy was omitted. Although the PV thrombus problem was resolved, the ABO antibody titers significantly increased, and two cases of uncontrollable humoral rejection (HR) were experienced. In this study, Rituximab was introduced instead of splenectomy to decrease the antibody. We report the efficacy of prophylaxis with Rituximab for ABO-I LDLT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0041-1345
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1718-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15919443-ABO Blood-Group System,
pubmed-meshheading:15919443-Adult,
pubmed-meshheading:15919443-Aged,
pubmed-meshheading:15919443-Antibodies, Monoclonal,
pubmed-meshheading:15919443-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15919443-Blood Group Incompatibility,
pubmed-meshheading:15919443-Drug Administration Schedule,
pubmed-meshheading:15919443-Female,
pubmed-meshheading:15919443-Hepatic Artery,
pubmed-meshheading:15919443-Humans,
pubmed-meshheading:15919443-Immunologic Factors,
pubmed-meshheading:15919443-Immunosuppression,
pubmed-meshheading:15919443-Infusions, Intra-Arterial,
pubmed-meshheading:15919443-Liver Transplantation,
pubmed-meshheading:15919443-Male,
pubmed-meshheading:15919443-Middle Aged,
pubmed-meshheading:15919443-Plasmapheresis,
pubmed-meshheading:15919443-Portal Vein,
pubmed-meshheading:15919443-Preoperative Care,
pubmed-meshheading:15919443-Spleen
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen.
|
|
pubmed:affiliation |
Kyoto University Graduate School of Medicine, Department of Transplantation and Immunology, Shougoin, Kyoto, Japan. ayoshi14@kuhp.kyoto-u.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
